Skip to main content
. 2023 Dec 11;14:1325462. doi: 10.3389/fimmu.2023.1325462

Figure 1.

Figure 1

Levels of sPD-1 (A) and sPD-L1 (B) in patients with head and neck cancer (HNC, n = 50), urothelial cancer (UC, n = 42), renal cell cancer (RCC, n = 37) gastric cancer (GC, n = 20), esophageal cancer (EC, n = 10), malignant pleural mesothelioma (MPM, n = 6), or microsatellite instability (MSI)–high cancer (n = 6).